Revive Therapeutics Ltd (RVVTF)

[MOONSHOT]

and partners, according to the SA article we should have enough funds to do phase 3

After speaking with management, the company has close to $2 million in cash to-date with over $4 million expected to come in from the exercise of warrants in the near term. Running a clinical trial of this size is expensive, especially one proposed to be with 1,000 patients. But management estimates that it will have sufficient funding to move forward with the project as planned.